These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 11702523)
21. 2005 Canadian Hypertension Education Program recommendations. New and important aspects of the sixth annual Canadian Hypertension Education Program's recommendations for management of hypertension. Evidence-Based Recommendations Task Force of the Canadian Hypertension Education Program Can Fam Physician; 2005 May; 51():702-5. PubMed ID: 15934274 [No Abstract] [Full Text] [Related]
22. Awareness of cardiovascular risk factors in ischaemic heart disease: implications during the projection of secondary prevention interventions. Montinaro S; Mazzetti S; Vasicuro C; Acquistapace F J Cardiovasc Med (Hagerstown); 2008 Oct; 9(10):1052-6. PubMed ID: 18799969 [TBL] [Abstract][Full Text] [Related]
23. [Prevention of ischemic heart disease by changing diet and anticholesteremic agents. Risk hysteria or evidence-based work of physicians?]. Stender S; Astrup AV Ugeskr Laeger; 2000 Jun; 162(26):3715. PubMed ID: 10925630 [No Abstract] [Full Text] [Related]
24. The altered homeostatic theory: A hypothesis proposed to be useful in understanding and preventing ischemic heart disease, hypertension, and diabetes--including reducing the risk of age and atherosclerosis. Hellstrom HR Med Hypotheses; 2007; 68(2):415-33. PubMed ID: 16828234 [TBL] [Abstract][Full Text] [Related]
25. Hypertensive therapy: Part II. Franco V; Oparil S; Carretero OA Circulation; 2004 Jun; 109(25):3081-8. PubMed ID: 15226224 [No Abstract] [Full Text] [Related]
34. Cardiovascular risk assessment and treatment to target low density lipoprotein levels in hospitalized ischemic heart disease patients: results of the HOLEM study. Harats D; Leibovitz E; Maislos M; Wolfovitz E; Chajek-Shaul T; Leitersdorf E; Gavish D; Gerber Y; Goldbourt U; Isr Med Assoc J; 2005 Jun; 7(6):355-9. PubMed ID: 15984375 [TBL] [Abstract][Full Text] [Related]
35. [Cracovian program for secondary prevention of ischemic heart disease. Secondary prevention of ischemic heart disease during hospitalization in 1996-97 and 1998-99]. Pajak A; Kawecka-Jaszcz K; Jankowski P; Bilo G; Dubiel JS; Maciejewicz J; Piotrowski W; Smielak-Korombel W; Tracz W Przegl Lek; 2003; 60(3):136-41. PubMed ID: 14575013 [TBL] [Abstract][Full Text] [Related]
36. [Disturbances in mitochondrial biosynthesis of acetyl-CoA and their role in the prevention of ischemic heart disease]. Burchardt P; Wiktorowicz K; Goździcka-Józefiak A; Parucki R; Wysocki H Kardiol Pol; 2008 Nov; 66(11):1215-20. PubMed ID: 19105101 [No Abstract] [Full Text] [Related]
37. Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. Bhatt DL J Invasive Cardiol; 2003 Mar; 15 Suppl B():3B-9B; discussion 9B-10B. PubMed ID: 12724580 [No Abstract] [Full Text] [Related]
38. Secondary prevention of ischemic heart disease: closing the gap. Fainaru M Isr Med Assoc J; 2005 Jun; 7(6):400-1. PubMed ID: 15984387 [No Abstract] [Full Text] [Related]
39. An approach of patients with ischemic stroke to primary and secondary stroke prevention in Poland. Nowacki P; Porebska A; Bajer-Czajkowska A; Zywica A; Koziarska D; Podbielski J Ann Acad Med Stetin; 2007; 53(2):14-9. PubMed ID: 18557372 [TBL] [Abstract][Full Text] [Related]
40. [Primary prevention of malignant tumors]. Gálová M; Bednarík O; Palácová M Cas Lek Cesk; 2002 Nov; 141(22):691-6. PubMed ID: 12532905 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]